Home › Hepatoblastoma
Hepatoblastoma clinical trials recruiting in the U.S.
11 studies for Hepatoblastoma are recruiting participants at sites across the United States.
Cities with the most studies
- Los Angeles, CA3 studies
- Boston, MA3 studies
- Atlanta, GA3 studies
- Cincinnati, OH3 studies
- Memphis, TN3 studies
By state
- California4 studies
- Georgia3 studies
- Massachusetts3 studies
- New York4 studies
- Ohio3 studies
- Tennessee3 studies
Recently updated studies
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Sep 1, 2026 · NCT04928677Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Molecular Basis of Pediatric Liver Cancer
RecruitingObservational study
Ages 0 to 99 · All sexes · Updated Aug 10, 2026 · NCT03959800ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RecruitingPhase 1/2
Ages 1 to 21 · All sexes · Updated Jul 6, 2026 · NCT04634357B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
RecruitingObservational study
All ages · All sexes · Updated Mar 18, 2026 · NCT05556642Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.